Table 3 Clinical trials with CSCs and secretome
NTC number | Target | Status | Drug | Combined therapy | Cancer type |
|---|---|---|---|---|---|
NCT01861054 | CXCR1 | Completed | Reparixin | Breast cancer | |
NCT02001974 | CXCR1 | Phase 1/completed | Reparixin | Paclitaxel | Breast cancer |
NCT01190345 | VEGF | Phase 2/completed | Bevacizumab | Chemotherapy | Breast cancer |
NCT01283945 | VEGFR/FGFR/PDGFR | Phase 1/2a completed | Lucitanib | Solid tumor | |
NCT02491840 | CXCR4 | Recruiting | Prognostic biomarkers | Gastric and cardia adenocarcinoma | |
NCT01955460 | TGF-ß | Phase 1/recruiting | Aldesleukin | Chemotherapy and lymphocytes | Melanoma |
NCT01248637 | HIF-1 | Completed | Pimonidazole hydrochloride | Pancreatic | |
NCT04137627 | HIF-1 | Phase 3/completed | Melatonin | Adjuvant chemotherapy | Oral squamous cell carcinoma |
NCT02499458 | HIF-2 | Completed | Biomarkers | Renal cancer | |
NCT03401788 | HIF-2 | Phase 2/not recruiting | PT2977 | VHL-associated renal cell carcinoma | |
NCT03108066 | HIF-2 | Phase 2/not recruiting | PT2385 | VHL-associated renal cell carcinoma | |
NCT01283945 | FGF | Phase ½ completed | Lucitanib | Solid tumors | |
NCT00657423 | FGF | Phase 3 | Endostar | Docetaxel and cisplatin | Lung neoplasms |
NCT01440959 | FGF | Phase 2/completed | Dovitinib | Gastrointestinal stromal tumors | |
NCT00372775 | FGF | Phase 2/completed | Sunitinib | Non-small cell lung cancer with brain metastasis | |
NCT01791985 | FGF | Phase 1 Phase 2 Completed | AZD4547 | Anastrozole or letrozole | Breast cancer |
NCT01945164 | FGF | Completed | XL999 | Advanced malignancies | |
NCT00021229 | FGF | Phase 1/2 | Imatinib mesylate | Local irradiation therapy | Glioma |
NCT04207086 | FGF | Phase 2/recruiting | Pembrolizumab Lenvatinib | Melanoma stage III | |
NCT03303885 | FGF | Recruiting | Preclinical biomarkers | Liposarcoma | |
NCT00216112 | PDGF | Phase 2/completed | Matinib, mesylate Docetaxel | Ovarian cancer | |
NCT03851614 | PDGF | Phase 2/recruiting | Cediranib | Durvalumab | Colorectal cancer Pancreatic adenocarcinoma Leiomyosarcoma |
NCT01372813 | PDGF | Phase 2/completed | Vandetanib | Renal carcinoma | |
NCT04042597 | PDGF | Phase 2/recruiting | Anlotinib hydrochloride | Chordoma advanced cancer | |
NCT00367679 | PDGF | Phase 2/completed | Pazopanib | Non-small cell lung cancer | |
NCT00372775 | PDGF | Phase 2/completed | Sunitinib | Non-small cell lung cancer | |
NCT01105533 | PDGF | Phase 1/completed | PF-00337210 | Neoplasm | |
NCT00600821 | PDGF | Phase 2/completed | AG-013736 (axitinib) | Paclitaxel and carboplatin | Non-small cell lung carcinoma |
NCT04207086 | PDGF | Phase 2/completed | Lenvatinib | Pembrolizumab | Melanoma stage III |
NCT02178072 | CCL5 | Phase 2/recruiting | 5-Azacitadine | Head and neck squamous cell carcinoma | |
NCT03126630 | CCL5 | Phase 1/2 recruiting | Pembroli Anetumab ravtansinezumab | Pleural malignant mesothelioma | |
NCT03964337 | CCL5 | Phase 2 | Cabozantinib | Prostate cancer | |
NCT02125344 | CCL5 | Phase 3/completed | Chemotherapy | Breast cancer | |
NCT02432378 | CCL5 | Phase ½ recruiting | Cisplatin and DC vaccine | Celecoxib CKM | Ovarian cancer |
NCT00653250 | PEG2 | Completed | Celecoxib | Lung cancer |